Attached files
file | filename |
---|---|
10-Q - JAVELIN PHARMACEUTICALS 10-Q - JAVELIN PHARMACEUTICALS, INC | javelin_10q-093009.htm |
EX-32.2 - CERTIFICATION - JAVELIN PHARMACEUTICALS, INC | javelin_10q-ex3202.htm |
EX-31.2 - CERTIFICATION - JAVELIN PHARMACEUTICALS, INC | javelin_10q-ex3102.htm |
EX-31.1 - CERTIFICATION - JAVELIN PHARMACEUTICALS, INC | javelin_10q-ex3101.htm |
Exhibit
32.1
CERTIFICATION
PURSUANT TO
18
U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report of Javelin Pharmaceuticals, Inc. (the
“Company”) on Form 10-Q for the period ended September 30, 2009, as filed
with the Securities and Exchange Commission on the date hereof (the “Report”),
I, Martin J. Driscoll, the Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934, as amended; and
(2) The information contained
in the Report fairly presents, in all material respects, the financial condition
and results of operations of the Company.
Date:
November 9, 2009
|
|
/s/ Martin J. Driscoll | |
Name:
Martin J. Driscoll
|
|||
Title:
Chief Executive Officer
|
A signed
original of this written statement required by Section 906 has been provided to
the Company and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.
This
certification accompanies each periodic report pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the
Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of
Section 18 of the Securities Exchange Act of 1934, as
amended.